Save your place

Sign in to WhoBought

Please try again later.

Recursion Pharmaceuticals, Inc. (RXRX) institutional ownership

Latest close $3.00 Jul 31, 2026
Market cap$2.4B 52-week range SectorHealthcare
Funds holding · Q1 2026
312
reported RXRX position changes
Top owners · Q2 2026
No disclosed owners are available.
Institutional activity · Q1 2026
Net bought $46M
185 buyers · 127 sellers

Recursion Pharmaceuticals, Inc. (RXRX) price and institutional activity

Dates

Q1 2026

$151M bought by 185 investors
BlackRock$17MGoldman Sachs Group Inc$15M +183 more
$105M sold by 127 investors
Norges-$22MCitadel Advisors LLC-$14M +125 more
Bought Sold Totals per quarter; hover a bar for the names.

Recursion Pharmaceuticals, Inc. (RXRX) institutional activity · 312

Investor Type Est. change Change Δ Own Date
Norges · Exited −$22M
Change −5.7M Δ Own −100.0% Date Q1 2026
Norges Exited· Q1 2026 −$22M −5.7M −100.0% Q1 2026
BlackRock · Added +$17M
Change +4.3M Date Q1 2026
BlackRock Added· Q1 2026 +$17M +4.3M Q1 2026
Goldman Sachs Group Inc · Added +$15M
Change +3.9M Date Q1 2026
Goldman Sachs Group Inc Added· Q1 2026 +$15M +3.9M Q1 2026
Citadel Advisors LLC Reduced· Q1 2026 −$14M −3.6M −85.2% Q1 2026
Morgan Stanley · Reduced −$13M
Change −3.5M Date Q1 2026
Morgan Stanley Reduced· Q1 2026 −$13M −3.5M Q1 2026
State Street · Added +$12M
Change +3.2M Date Q1 2026
State Street Added· Q1 2026 +$12M +3.2M Q1 2026
Ark Investment Management LLC Added· Q1 2026 +$11M +2.9M +7.8% Q1 2026
Marshall Wace, LLP · Added +$10M
Change +2.7M Date Q1 2026
Marshall Wace, LLP Added· Q1 2026 +$10M +2.7M Q1 2026
FMR LLC · Reduced −$9.7M
Change −2.5M Δ Own −77.3% Date Q1 2026
FMR LLC Reduced· Q1 2026 −$9.7M −2.5M −77.3% Q1 2026
Renaissance Technologies LLC New· Q1 2026 +$9.3M +2.4M Q1 2026
Vanguard · Added +$8.0M
Change +2.1M Date Q1 2026
Vanguard Added· Q1 2026 +$8.0M +2.1M Q1 2026
UBS Group AG · Added +$5.4M
Change +1.4M Date Q1 2026
UBS Group AG Added· Q1 2026 +$5.4M +1.4M Q1 2026
Geode · Added +$5.2M
Change +1.3M Date Q1 2026
Geode Added· Q1 2026 +$5.2M +1.3M Q1 2026
Barclays PLC · Reduced −$5.1M
Change −1.3M Date Q1 2026
Barclays PLC Reduced· Q1 2026 −$5.1M −1.3M Q1 2026
Man Group PLC · Added +$4.5M
Change +1.2M Date Q1 2026
Man Group PLC Added· Q1 2026 +$4.5M +1.2M Q1 2026
Data through Q1 2026 · filed Jun 9, 2026
15 of 312

Famous investor activity in Recursion Pharmaceuticals, Inc. (RXRX)

Recursion Pharmaceuticals, Inc. (RXRX) insider trading

Company insiders, action and economics first; trade and filed dates last.
Dates
Insider Title Type Price Qty Value Owned ΔOwn Trade date Filed date
Borgeson Blake · Director Sell −$158K
Price $3.96 Qty −40K Owned 6.2M ΔOwn −0.6% Trade date Jul 7, 2026 Filed date Jul 9, 2026
Borgeson Blake Director Sell $3.96 −40K −$158K 6.2M −0.6% Jul 7, 2026 Jul 9, 2026
Dar Zavain · Director Grant (A) 5K
Owned 241K ΔOwn +2.2% Trade date Jul 1, 2026 Filed date Jul 2, 2026
Dar Zavain Director Grant (A) 5K 241K +2.2% Jul 1, 2026 Jul 2, 2026
Li Dean Y. · Director Grant (A) 4K
Owned 1.5M ΔOwn +0.3% Trade date Jul 1, 2026 Filed date Jul 2, 2026
Li Dean Y. Director Grant (A) 4K 1.5M +0.3% Jul 1, 2026 Jul 2, 2026
Bumpus Namandje · Director Sell −$13K
Price $3.18 Qty −4K Owned 128K ΔOwn −3.0% Trade date Jun 18, 2026 Filed date Jun 22, 2026
Bumpus Namandje Director Sell $3.18 −4K −$13K 128K −3.0% Jun 18, 2026 Jun 22, 2026
Borgeson Blake · Director Grant (A) 88K
Owned 6.3M ΔOwn +1.4% Trade date Jun 17, 2026 Filed date Jun 22, 2026
Borgeson Blake Director Grant (A) 88K 6.3M +1.4% Jun 17, 2026 Jun 22, 2026
Hershberg Robert · Director Grant (A) 88K
Owned 162K ΔOwn +119.9% Trade date Jun 17, 2026 Filed date Jun 22, 2026
Hershberg Robert Director Grant (A) 88K 162K +119.9% Jun 17, 2026 Jun 22, 2026
Michor Franziska · Director Grant (A) 88K
Owned 215K ΔOwn +69.6% Trade date Jun 17, 2026 Filed date Jun 22, 2026
Michor Franziska Director Grant (A) 88K 215K +69.6% Jun 17, 2026 Jun 22, 2026
Sun Elaine D. · Director Grant (A) 88K
Owned 136K ΔOwn +185.9% Trade date Jun 17, 2026 Filed date Jun 22, 2026
Sun Elaine D. Director Grant (A) 88K 136K +185.9% Jun 17, 2026 Jun 22, 2026
Dar Zavain · Director Grant (A) 88K
Owned 236K ΔOwn +60.1% Trade date Jun 17, 2026 Filed date Jun 22, 2026
Dar Zavain Director Grant (A) 88K 236K +60.1% Jun 17, 2026 Jun 22, 2026
Li Dean Y. · Director Grant (A) 88K
Owned 1.5M ΔOwn +6.4% Trade date Jun 17, 2026 Filed date Jun 22, 2026
Li Dean Y. Director Grant (A) 88K 1.5M +6.4% Jun 17, 2026 Jun 22, 2026
Bumpus Namandje · Director Grant (A) 88K
Owned 132K ΔOwn +204.8% Trade date Jun 17, 2026 Filed date Jun 22, 2026
Bumpus Namandje Director Grant (A) 88K 132K +204.8% Jun 17, 2026 Jun 22, 2026
Taylor Ben R. · CFO Tax withholding or exercise payment (F) -$17K
Price $3.15 Qty -5K Owned 1.1M Trade date Jun 15, 2026 Filed date Jun 17, 2026
Taylor Ben R. CFO Tax withholding or exercise payment (F) $3.15 -5K -$17K 1.1M Jun 15, 2026 Jun 17, 2026
Gibson Christopher · Director Sell −$145K
Price $3.62 Qty −40K Owned 884K Trade date Jun 5, 2026 Filed date Jun 5, 2026
Gibson Christopher Director Sell $3.62 −40K −$145K 884K Jun 5, 2026 Jun 5, 2026
Gibson Christopher · Director 2 operations 0
Owned 4.3M Trade date Jun 5, 2026 Filed date Jun 5, 2026
Gibson Christopher Director 2 operations 0 4.3M Jun 5, 2026 Jun 5, 2026
Khan Najat · Director Sell −$84K
Price $3.58 Qty −24K Owned 2.2M Trade date Jun 5, 2026 Filed date Jun 5, 2026
Khan Najat Director Sell $3.58 −24K −$84K 2.2M Jun 5, 2026 Jun 5, 2026
15 of 61
15 of 61 Sign in to continue to older insider transactions.

Recursion Pharmaceuticals, Inc. (RXRX) activist and large shareholders

Dates
Owner/Filer identity Shares reported % of shares outstanding Filing date
Baillie Gifford & Co 24.2M
% of shares outstanding 11.6% Filing date Jan 26, 2024
Baillie Gifford & Co 24.2M 11.6% Jan 26, 2024
Ark Investment Management LLC 23.1M
% of shares outstanding 11.1% Filing date Feb 12, 2024
Ark Investment Management LLC 23.1M 11.1% Feb 12, 2024
Blackrock, Inc. 44.5M
% of shares outstanding 8.5% Filing date Jul 29, 2026
Blackrock, Inc. 44.5M 8.5% Jul 29, 2026
Blackrock, Inc. 37.8M
% of shares outstanding 7.2% Filing date Apr 24, 2026
Blackrock, Inc. 37.8M 7.2% Apr 24, 2026
Mubadala Investment Co Pjsc 11.3M
% of shares outstanding 6.3% Filing date Oct 31, 2022
Mubadala Investment Co Pjsc 11.3M 6.3% Oct 31, 2022
BlackRock Inc. 12.4M
% of shares outstanding 6.0% Filing date Jan 29, 2024
BlackRock Inc. 12.4M 6.0% Jan 29, 2024
Vanguard Portfolio Management 31.4M
% of shares outstanding 6.0% Filing date Jul 31, 2026
Vanguard Portfolio Management 31.4M 6.0% Jul 31, 2026
Ra Capital Management, L.P. 15.4M
% of shares outstanding 5.9% Filing date Jul 8, 2024
Ra Capital Management, L.P. 15.4M 5.9% Jul 8, 2024
8 of 15

Recursion Pharmaceuticals, Inc. (RXRX) ownership FAQ

Who owns RXRX?

312 reporting institutions disclosed RXRX position changes in the Q1 2026 snapshot.

How is institutional activity calculated?

For each manager, WhoBought compares accepted consecutive 13F share counts. Share change is current shares minus prior shares. Estimated dollar change is that signed share change multiplied by the split-adjusted quarter-mean close. The activity table on this page uses Q1 2026.

What are activist and large shareholder filings?

An investor crossing 5% of a share class generally files Schedule 13D for activist intent or Schedule 13G for a passive position. The technical form names appear here rather than in the activity rows.

Where does this data come from?

Ownership and institutional activity come from SEC Form 13F filings. Insider activity comes from SEC Form 4, and large-shareholder activity from SEC Schedules 13D and 13G. FMP supplies price data only. Company logos use the local verified Parqet cache with one shared fallback.

Why are ownership reports delayed?

Form 13F is a quarterly disclosure and is normally filed after the quarter ends. Every ownership and activity value therefore names its represented period; it is not presented as a live position.

How are missing table values shown?

A muted dash marks a missing table value. It means the filing omitted the value, comparable data is unavailable, or no prior position exists for comparison.